Osimertinib (Tagrisso®) Adjuvant treatment stage IB-IIIA NSCLC. HTA ID: 21066

Assessment Status NCPE Assessment Process Complete
HTA ID 21066
Drug Osimertinib
Brand Tagrisso®
Indication For adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Assessment Process
Rapid review commissioned 20/12/2021
Rapid review completed 13/01/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/01/2022
Pre-submission consultation with Applicant 15/03/2022
Full submission received from Applicant 16/08/2022
Preliminary review sent to Applicant 27/01/2023
NCPE assessment re-commenced 13/03/2023
Factual accuracy sent to Applicant 03/05/2023
NCPE assessment re-commenced 10/05/2023
NCPE assessment completed 23/05/2023
NCPE assessment outcome The NCPE recommends that osimertinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.